Research Topics
Genomes and Genes
| Angela DeMicheleSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohortAngela DeMichele
Department of Biostatistics and Epidemiology, Abramson Cancer Center, PA, USA
J Clin Oncol 23:5552-9. 2005..Genotypes in drug-metabolizing enzymes, including functional polymorphisms in cytochrome P450 (CYP) and glutathione S-transferases (GST), may predict treatment-related outcomes...- Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patientsAngela DeMichele
Division of Hematology Oncology, Department of Medicine, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer 97:2150-9. 2003.... - Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancerAngela DeMichele
Department of Medicine Heme Onc, Rowan Breast Center of the Abramson Cancer Center, University of Pennsylvania, 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 63:8051-6. 2003..Additional studies are needed to confirm these results and elucidate the mechanisms responsible for these differences... - Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiologyTimothy R Rebbeck
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
Cancer Epidemiol Biomarkers Prev 16:444-50. 2007.... 
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivorsH Irene Su
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA 19146, USA
Fertil Steril 94:645-54. 2010..To determine if genetic variation in chemotherapy metabolism are associated with risk of ovarian failure in breast cancer patients after adjuvant chemotherapy...- Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer riskTimothy R Rebbeck
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA
Cancer Epidemiol Biomarkers Prev 16:1318-20. 2007 - Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American womenTimothy R Rebbeck
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Carcinogenesis 30:269-74. 2009..We further report that these genes confer their effects in HER2- tumors, interact with one another to confer breast cancer susceptibility in AA women and interact with hormone exposures in AA and EA women... - Risk factors for lymphedema after breast cancer treatmentSandra A Norman
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
Cancer Epidemiol Biomarkers Prev 19:2734-46. 2010..As cancer treatments evolve, it is important to reevaluate their effect on lymphedema risk in breast cancer survivors... - A retrospective case-control study of the use of hormone-related supplements and association with breast cancerTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
Int J Cancer 120:1523-8. 2007..Additional confirmatory studies are required to determine whether black cohosh could be used to prevent breast cancer... - Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control studyAngela DeMichele
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 26:4151-9. 2008.... 
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancerAngela DeMichele
Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Cancer Res 69:4184-91. 2009..Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41)...- Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapyDavid R Busch
Dept of Physics and Astronomy, University of Pennsylvania, 209 S 33rd St, Philadelphia, PA 19104 USA
Biomed Opt Express 4:105-21. 2013..Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes... - Case-control study of postmenopausal hormone replacement therapy and endometrial cancerBrian L Strom
Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, 19104 6021, USA
Am J Epidemiol 164:775-86. 2006..Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen... - Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivorsJames J Mao
Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
Integr Cancer Ther 8:123-9. 2009..Given the existing evidence for electroacupuncture (EA) for treatment of osteoarthritis in the general population, this study aims to establish the feasibility of studying EA for treating AI-related arthralgia... - Computer aided automatic detection of malignant lesions in diffuse optical mammographyDavid R Busch
Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Med Phys 37:1840-9. 2010..The methodology is tested in a population of 35 biopsy-confirmed malignant lesions... - Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomographyRegine Choe
University of Pennsylvania, Department of Physics, 209 S 33rd Street, Philadelphia, Pennsylvania 19104, USA
J Biomed Opt 14:024020. 2009..90 to 0.99, suggesting good discriminatory power. The data demonstrate that benign and malignant lesions can be distinguished by quantitative three-dimensional DOT... - Genomic predictors of outcome and treatment response in breast cancerLara Dunn
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mol Diagn Ther 13:73-90. 2009..Gene signatures have the potential to transform breast cancer treatment as it becomes tailored to each patient's tumor expression profile and significantly improve the outcomes of this disease... - Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategiesRebecca M Speck
Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, 1121A Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
Support Care Cancer 21:549-55. 2013..This study examined the experience and coping strategies for taste alteration in female breast cancer patients treated with docetaxel or paclitaxel... - Vitamin d deficiency in postmenopausal breast cancer survivorsClaire F Friedman
Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
J Womens Health (Larchmt) 21:456-62. 2012..Given the role vitamin D plays in bone metabolism, we examined the prevalence of and risk factors for vitamin D deficiency in a study of postmenopausal BCS on AIs... - Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcomeVandana Gupta Abramson
Department of Medicine, University of Pennsylvania, PA, USA
Anticancer Res 30:1279-85. 2010..Our objectives were to determine whether cyclin D1b is expressed in human breast carcinomas and to characterize the relationship of this protein to both cyclin D1a and clinical outcome in breast cancer patients... - Predictors of yoga use among patients with breast cancerKrupali Desai
Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA 19104
Explore (NY) 6:359-63. 2010..However, very little is known about the characteristics of breast cancer patients who use yoga; thus, this study seeks to identify the sociodemographic and clinical characteristics of yoga users among this population... - Delivery of survivorship care by primary care physicians: the perspective of breast cancer patientsJun J Mao
Department of Family Medicine and Community Health, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
J Clin Oncol 27:933-8. 2009..This study aims to describe postmenopausal breast cancer survivors' (BCS) perceptions of PCP-related survivorship care... - CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patientsAndrew J Rech
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Sci Transl Med 4:134ra62. 2012..We conclude that CD25 blockade depletes and selectively reprograms T(regs) in concert with active immune therapy in cancer patients. These results suggest a mechanism to target cancer-associated T(regs) while avoiding autoimmunity... - Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillanceSusan M Domchek
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer Res 67:10546-55. 2007..These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer... - Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patientsSteven C Palmer
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
Psychosom Med 66:258-64. 2004..We examined the relationships between the experience of trauma, psychological distress, and PTSD among a waiting room sample of patients with breast cancer... - Is screening effective in detecting untreated psychiatric disorders among newly diagnosed breast cancer patients?Steven C Palmer
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Cancer 118:2735-43. 2012..This study adopts the novel strategy of evaluating the effectiveness of screening after correcting for disorder for which treatment is already being provided... - Adult cancer survivorship: evolution, research, and planning careLinda A Jacobs
LIVESTRONG Survivorship Center of Excellence Abramson Cancer Center, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania 19104, USA
CA Cancer J Clin 59:391-410. 2009..Finally, an overview of evolving treatment summary and care plan initiatives is presented... - Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivorsJun J Mao
Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, 3400 Spruce Street 2 Gates, Philadelphia, PA 19104, USA
Breast Cancer Res 13:R8. 2011.... - Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivorsH Irene Su
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer 116:592-9. 2010.... - Experiences with weight change in African-American breast cancer survivorsChanita Hughes Halbert
Department of Psychiatry, Abramson Cancer Center, and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Breast J 14:182-7. 2008..It may be important to provide African-American breast cancer survivors with information about the causes and implications of weight change and strategies for weight control after treatment as part of their follow-up care... - Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer riskTimothy R Rebbeck
Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104 6021, USA
J Natl Cancer Inst 98:1311-20. 2006..To investigate the mechanism of this association, we evaluated whether risk of endometrial cancer was associated with the genotypes involved in steroid hormone metabolism and the duration of exogenous hormone use... - Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitorsKrupali Desai
Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street, 2 Gates Building, Philadelphia, PA 19104, USA
Support Care Cancer 21:43-51. 2013.... - The role of lapatinib in the preoperative therapy of breast cancerRebecca L Hirsh
Division of Hematology Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Curr Oncol Rep 14:44-7. 2012..Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer... - Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivorsJun J Mao
Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA, USA
Cancer 115:3631-9. 2009..The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA)... - Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretionBrian J Czerniecki
Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 67:1842-52. 2007..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer... - Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptomsSandra A Norman
Department of Medicine, Division of Hematology Oncology, Center for Clinical Epidemiologyand Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
J Clin Oncol 27:390-7. 2009..To examine the incidence, degree, time course, treatment, and symptoms of lymphedema in breast cancer survivors... - Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancerSarah Kim
Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
Immunol Invest 38:324-40. 2009..While much remains to be learned about the mechanisms underlying these variants and their impact on tumor behavior, this area holds promise for future development of prognostic profiles and therapeutics exploiting the immune response... - Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patientsRebecca M Speck
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
Support Care Cancer 20:2433-9. 2012..We also examined the variety of taxane-related side effects in women with and without CIPN in order to discriminate the CIPN symptom experience... - Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Cancer Res 18:568-76. 2012.... - The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapyEleanor E R Harris
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
Breast J 12:431-6. 2006..15). There was no difference in local recurrence after BCT between HER-2-positive and negative breast cancers at 5 years. Therefore HER-2 overexpression does not appear to be a contraindication to BCT... - Morbidity and mortality of colorectal carcinoma surgery differs by insurance statusRachel Rapaport Kelz
Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Cancer 101:2187-94. 2004.... - Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRIRegine Choe
Department of Physics and Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104 6396, USA
Med Phys 32:1128-39. 2005..A decrease in total hemoglobin concentration contrast between tumor and normal tissue was also observed over time. The results demonstrate the potential of DOT for measuring physiological parameters of breast lesions during chemotherapy... - Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivorsEdwin Rock
Division of Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Nutr 133:3785S-3793S. 2003..However, except for vitamin D and calcium for prevention of bone loss, current clinical evidence supporting use of nutritional agents remains sparse... - The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancerStephen M Keefe
Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
Curr Oncol Rep 12:22-5. 2010..As yet, combination regimens have failed to demonstrate a survival advantage. Emerging research suggests that single-nucleotide polymorphism in VEGF may predict response to combined therapy... - Association of catechol-O-methyltransferase with smoking cessation in two independent studies of womenSusan Colilla
Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Pharmacogenet Genomics 15:393-8. 2005..To determine if the lower activity Met allele of COMT was associated with smoking cessation in women, we used two independent studies: a population-based case--control study and a nicotine replacement clinical trial... - mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cellsXiaojun Yang
Ovarian Cancer Research Center and Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
Biochem Biophys Res Commun 431:617-22. 2013..This result will contribute to understanding the molecular mechanism of mir-30d in tumorigenesis and developing novel cancer therapy strategy... - Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sampleJames C Coyne
Departments of Psychiatry and Hematology Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA
Gen Hosp Psychiatry 26:121-8. 2004..The low rate of untreated psychiatric morbidity may signal a need for multisite collaborations to generate adequate numbers of participants in clinical trials... - Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxisLeslie S Kersun
Department of Pediatrics, Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Pediatr Blood Cancer 45:162-9. 2005..Our purpose was to determine the incidence of bacteremia and antimicrobial resistance post-HSCT in pediatric patients receiving GD, and to identify risk factors associated with infection... - Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerLin Zhang
Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 105:7004-9. 2008..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer... - Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R)Enkhtsetseg Purev
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
J Immunol 173:6472-80. 2004.... - In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort"Angela DeMichele
J Clin Oncol 25:5675-7. 2007 - Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendationsLois B Travis
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
J Natl Cancer Inst 98:15-25. 2006..These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer... - Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patientsKaren Smith
Department of Oncology-Hematology, Memorial-Sloan Kettering Cancer Center, USA
Clin Breast Cancer 6:260-6; discussion 267-9. 2005..Strategies aimed at improving psychosocial barriers to adjuvant therapy and at reducing surgical complications in black patients may improve overall breast cancer outcomes in this group... - Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerFrancisco J Esteva
University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
J Clin Oncol 21:999-1006. 2003..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent... - Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posedAngela DeMichele
J Clin Oncol 20:1164-6. 2002
Research Grants
- AGE, CELL CYCLE MARKERS AND BREAST CANCER OUTCOMESAngela DeMichele; Fiscal Year: 2004..abstract_text> ..
- Molecular & Genetic Determinants of Outcome in Breast CancerAngela DeMichele; Fiscal Year: 2007....